Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alopecia | 23 | 2020 | 31 | 8.320 |
Why?
|
| African Americans | 22 | 2020 | 1435 | 3.360 |
Why?
|
| Skin Pigmentation | 10 | 2020 | 27 | 3.200 |
Why?
|
| Scalp Dermatoses | 8 | 2021 | 18 | 2.890 |
Why?
|
| Hair | 9 | 2019 | 31 | 2.840 |
Why?
|
| Scalp | 10 | 2020 | 38 | 2.570 |
Why?
|
| Hair Preparations | 12 | 2020 | 12 | 2.530 |
Why?
|
| Alopecia Areata | 14 | 2020 | 16 | 2.450 |
Why?
|
| Cicatrix | 8 | 2020 | 41 | 2.130 |
Why?
|
| Lichen Planus | 5 | 2021 | 10 | 2.010 |
Why?
|
| Dermatology | 8 | 2020 | 164 | 1.800 |
Why?
|
| Minoxidil | 5 | 2017 | 6 | 1.620 |
Why?
|
| Hyperpigmentation | 8 | 2018 | 17 | 1.570 |
Why?
|
| Humans | 89 | 2021 | 34475 | 1.470 |
Why?
|
| Skin Diseases | 4 | 2020 | 148 | 1.460 |
Why?
|
| Dermatologic Agents | 11 | 2020 | 235 | 1.300 |
Why?
|
| Acne Vulgaris | 7 | 2019 | 102 | 1.200 |
Why?
|
| Ethnic Groups | 7 | 2020 | 483 | 1.160 |
Why?
|
| Hair Removal | 4 | 2012 | 5 | 1.150 |
Why?
|
| African Continental Ancestry Group | 7 | 2017 | 367 | 1.120 |
Why?
|
| Middle Aged | 34 | 2020 | 12703 | 1.030 |
Why?
|
| Adult | 34 | 2020 | 10015 | 1.010 |
Why?
|
| Female | 46 | 2020 | 21491 | 1.010 |
Why?
|
| Severity of Illness Index | 14 | 2020 | 922 | 0.930 |
Why?
|
| Patient Satisfaction | 5 | 2016 | 245 | 0.930 |
Why?
|
| Glucocorticoids | 5 | 2020 | 154 | 0.900 |
Why?
|
| Cultural Diversity | 3 | 2020 | 21 | 0.830 |
Why?
|
| European Continental Ancestry Group | 6 | 2019 | 1176 | 0.830 |
Why?
|
| Internship and Residency | 3 | 2020 | 330 | 0.810 |
Why?
|
| Psoriasis | 3 | 2019 | 362 | 0.800 |
Why?
|
| Laser Therapy | 5 | 2012 | 56 | 0.780 |
Why?
|
| Skin | 4 | 2019 | 222 | 0.760 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 168 | 0.690 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2021 | 6 | 0.680 |
Why?
|
| Hair Diseases | 3 | 2007 | 4 | 0.680 |
Why?
|
| Photochemotherapy | 1 | 2021 | 21 | 0.660 |
Why?
|
| Dermoscopy | 1 | 2020 | 12 | 0.650 |
Why?
|
| Triamcinolone Acetonide | 1 | 2020 | 4 | 0.630 |
Why?
|
| Delusions | 1 | 2019 | 3 | 0.620 |
Why?
|
| Psychophysiologic Disorders | 1 | 2019 | 5 | 0.620 |
Why?
|
| Lasers, Solid-State | 3 | 2020 | 8 | 0.620 |
Why?
|
| Hypopigmentation | 1 | 2019 | 7 | 0.610 |
Why?
|
| Pityriasis Lichenoides | 1 | 2019 | 4 | 0.610 |
Why?
|
| Continental Population Groups | 3 | 2020 | 245 | 0.600 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 318 | 0.600 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 446 | 0.600 |
Why?
|
| Exercise | 2 | 2016 | 700 | 0.600 |
Why?
|
| Forehead | 2 | 2019 | 13 | 0.590 |
Why?
|
| Dietary Supplements | 2 | 2017 | 197 | 0.590 |
Why?
|
| Skin Diseases, Viral | 1 | 2019 | 4 | 0.590 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2019 | 4 | 0.590 |
Why?
|
| Herpes Zoster | 1 | 2019 | 12 | 0.580 |
Why?
|
| United States | 16 | 2020 | 4267 | 0.570 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 270 | 0.560 |
Why?
|
| Young Adult | 11 | 2018 | 2825 | 0.560 |
Why?
|
| Radiotherapy | 1 | 2018 | 90 | 0.560 |
Why?
|
| Quality of Life | 7 | 2019 | 1032 | 0.550 |
Why?
|
| Parabens | 1 | 2018 | 1 | 0.550 |
Why?
|
| Sulfates | 1 | 2018 | 4 | 0.550 |
Why?
|
| Dermatitis, Atopic | 1 | 2019 | 103 | 0.540 |
Why?
|
| Barbering | 2 | 2017 | 2 | 0.540 |
Why?
|
| Hygiene | 2 | 2015 | 13 | 0.530 |
Why?
|
| Treatment Outcome | 12 | 2020 | 3618 | 0.530 |
Why?
|
| Occupational Exposure | 2 | 2016 | 237 | 0.520 |
Why?
|
| Male | 28 | 2019 | 20697 | 0.520 |
Why?
|
| Adjuvants, Immunologic | 2 | 2010 | 63 | 0.510 |
Why?
|
| Vitamins | 1 | 2017 | 75 | 0.500 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 230 | 0.500 |
Why?
|
| Health Education | 1 | 2017 | 170 | 0.490 |
Why?
|
| Hispanic Americans | 4 | 2016 | 948 | 0.490 |
Why?
|
| Keloid | 2 | 2013 | 8 | 0.490 |
Why?
|
| Skin Care | 1 | 2016 | 13 | 0.480 |
Why?
|
| Pigmentation Disorders | 2 | 2014 | 8 | 0.480 |
Why?
|
| Biological Products | 1 | 2017 | 80 | 0.480 |
Why?
|
| Adolescent | 14 | 2019 | 3799 | 0.470 |
Why?
|
| Beauty | 2 | 2013 | 5 | 0.470 |
Why?
|
| Plant Extracts | 1 | 2016 | 64 | 0.460 |
Why?
|
| Research Design | 2 | 2017 | 337 | 0.460 |
Why?
|
| Asian Continental Ancestry Group | 2 | 2014 | 109 | 0.440 |
Why?
|
| Cosmetic Techniques | 2 | 2017 | 11 | 0.430 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 222 | 0.430 |
Why?
|
| Cross-Sectional Studies | 6 | 2020 | 1607 | 0.420 |
Why?
|
| Foot Diseases | 1 | 2014 | 12 | 0.420 |
Why?
|
| Urea | 1 | 2014 | 39 | 0.420 |
Why?
|
| Lasers, Excimer | 1 | 2013 | 8 | 0.410 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 627 | 0.410 |
Why?
|
| Keratins, Hair-Specific | 1 | 2013 | 1 | 0.400 |
Why?
|
| Formaldehyde | 1 | 2013 | 15 | 0.400 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 540 | 0.380 |
Why?
|
| Lip | 1 | 2012 | 7 | 0.370 |
Why?
|
| Child | 8 | 2018 | 2613 | 0.370 |
Why?
|
| Lice Infestations | 1 | 2011 | 1 | 0.360 |
Why?
|
| Biopsy | 4 | 2019 | 268 | 0.350 |
Why?
|
| Neoplasms | 1 | 2018 | 791 | 0.350 |
Why?
|
| Health Behavior | 1 | 2013 | 246 | 0.340 |
Why?
|
| Administration, Topical | 5 | 2020 | 146 | 0.330 |
Why?
|
| Osteoma | 1 | 2010 | 1 | 0.330 |
Why?
|
| Injections, Intralesional | 3 | 2020 | 16 | 0.330 |
Why?
|
| Facial Neoplasms | 1 | 2010 | 9 | 0.330 |
Why?
|
| Aged | 13 | 2016 | 10999 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 565 | 0.320 |
Why?
|
| Aminoquinolines | 1 | 2010 | 18 | 0.320 |
Why?
|
| Palate | 1 | 2009 | 4 | 0.290 |
Why?
|
| Hypertrichosis | 1 | 2009 | 3 | 0.290 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2008 | 5 | 0.280 |
Why?
|
| Surgical Flaps | 1 | 2009 | 78 | 0.280 |
Why?
|
| Isotretinoin | 3 | 2016 | 13 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 364 | 0.270 |
Why?
|
| Phototherapy | 3 | 2020 | 51 | 0.270 |
Why?
|
| Hot Temperature | 1 | 2007 | 89 | 0.260 |
Why?
|
| Photography | 3 | 2017 | 45 | 0.260 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2009 | 202 | 0.250 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2020 | 123 | 0.250 |
Why?
|
| Dermatitis, Seborrheic | 2 | 2017 | 4 | 0.250 |
Why?
|
| Postoperative Complications | 1 | 2012 | 849 | 0.250 |
Why?
|
| Melanosis | 3 | 2020 | 15 | 0.240 |
Why?
|
| Rosacea | 2 | 2017 | 46 | 0.230 |
Why?
|
| Cosmetics | 3 | 2019 | 11 | 0.230 |
Why?
|
| Irritants | 1 | 2004 | 2 | 0.220 |
Why?
|
| Retrospective Studies | 4 | 2020 | 3812 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 152 | 0.210 |
Why?
|
| Sunscreening Agents | 2 | 2019 | 13 | 0.210 |
Why?
|
| Data Collection | 3 | 2017 | 191 | 0.210 |
Why?
|
| Health Care Surveys | 3 | 2015 | 191 | 0.200 |
Why?
|
| Age Factors | 3 | 2020 | 1262 | 0.200 |
Why?
|
| Sex Factors | 4 | 2015 | 707 | 0.200 |
Why?
|
| Pesticides | 1 | 2016 | 201 | 0.200 |
Why?
|
| Immunologic Factors | 1 | 2003 | 54 | 0.200 |
Why?
|
| Administration, Oral | 2 | 2020 | 212 | 0.190 |
Why?
|
| Double-Blind Method | 4 | 2019 | 597 | 0.190 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 248 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 304 | 0.190 |
Why?
|
| Comorbidity | 3 | 2014 | 596 | 0.190 |
Why?
|
| Skin Ulcer | 1 | 2002 | 12 | 0.180 |
Why?
|
| Herpes Simplex | 1 | 2002 | 14 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2002 | 20 | 0.180 |
Why?
|
| Child, Preschool | 3 | 2014 | 1354 | 0.180 |
Why?
|
| Erythema | 1 | 2002 | 25 | 0.180 |
Why?
|
| Office Visits | 2 | 2015 | 73 | 0.180 |
Why?
|
| Aminolevulinic Acid | 1 | 2021 | 9 | 0.170 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2020 | 4 | 0.170 |
Why?
|
| Prevalence | 3 | 2019 | 1034 | 0.170 |
Why?
|
| Case-Control Studies | 3 | 2016 | 924 | 0.170 |
Why?
|
| Photosensitizing Agents | 1 | 2021 | 23 | 0.170 |
Why?
|
| Injections, Intradermal | 1 | 2020 | 8 | 0.170 |
Why?
|
| Physician-Patient Relations | 2 | 2012 | 188 | 0.160 |
Why?
|
| Bibliometrics | 1 | 2020 | 11 | 0.160 |
Why?
|
| Risk Factors | 5 | 2016 | 4136 | 0.160 |
Why?
|
| Hypochondriasis | 1 | 2019 | 1 | 0.160 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2019 | 2 | 0.160 |
Why?
|
| S100 Proteins | 1 | 2019 | 19 | 0.150 |
Why?
|
| Drug Compounding | 2 | 2018 | 36 | 0.150 |
Why?
|
| Publishing | 1 | 2020 | 66 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 31 | 0.150 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2018 | 5 | 0.150 |
Why?
|
| Methotrexate | 1 | 2019 | 71 | 0.150 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 251 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 489 | 0.140 |
Why?
|
| Dapsone | 1 | 2018 | 5 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 49 | 0.140 |
Why?
|
| North Carolina | 4 | 2016 | 1612 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2019 | 438 | 0.130 |
Why?
|
| Infant | 2 | 2014 | 1122 | 0.130 |
Why?
|
| Cultural Competency | 1 | 2017 | 18 | 0.130 |
Why?
|
| Internet | 2 | 2018 | 207 | 0.130 |
Why?
|
| Administration, Cutaneous | 3 | 2015 | 119 | 0.130 |
Why?
|
| Vaccination | 1 | 2019 | 153 | 0.130 |
Why?
|
| Disease Progression | 1 | 2019 | 633 | 0.130 |
Why?
|
| Demography | 1 | 2017 | 112 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 849 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2009 | 124 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 352 | 0.120 |
Why?
|
| Mutation | 1 | 2019 | 529 | 0.120 |
Why?
|
| Keratolytic Agents | 3 | 2005 | 29 | 0.120 |
Why?
|
| Pharmaceutical Solutions | 1 | 2016 | 2 | 0.120 |
Why?
|
| Finasteride | 1 | 2016 | 5 | 0.120 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 26 | 0.120 |
Why?
|
| Off-Label Use | 1 | 2016 | 15 | 0.120 |
Why?
|
| Constipation | 1 | 2016 | 12 | 0.120 |
Why?
|
| Hydroquinones | 2 | 2014 | 7 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2017 | 193 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 91 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2017 | 138 | 0.120 |
Why?
|
| Decision Making | 1 | 2018 | 203 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 325 | 0.120 |
Why?
|
| Facial Dermatoses | 2 | 2006 | 18 | 0.120 |
Why?
|
| Cellulitis | 1 | 2015 | 12 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 429 | 0.110 |
Why?
|
| Deafness | 1 | 2014 | 1 | 0.110 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2014 | 1 | 0.110 |
Why?
|
| Acne Keloid | 1 | 2014 | 2 | 0.100 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2014 | 22 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 1118 | 0.100 |
Why?
|
| Retinoids | 1 | 2014 | 43 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2014 | 730 | 0.100 |
Why?
|
| Educational Status | 2 | 2011 | 185 | 0.100 |
Why?
|
| Triamcinolone | 1 | 2013 | 12 | 0.100 |
Why?
|
| Incidence | 2 | 2007 | 1289 | 0.090 |
Why?
|
| Pruritus | 1 | 2012 | 47 | 0.090 |
Why?
|
| Sensory Receptor Cells | 1 | 2012 | 37 | 0.090 |
Why?
|
| Vasodilator Agents | 2 | 2015 | 69 | 0.090 |
Why?
|
| Lasers, Semiconductor | 1 | 2011 | 1 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2012 | 113 | 0.090 |
Why?
|
| Caregivers | 1 | 2012 | 116 | 0.080 |
Why?
|
| Time Factors | 1 | 2016 | 2352 | 0.080 |
Why?
|
| Ointments | 1 | 2010 | 24 | 0.080 |
Why?
|
| Keratosis, Actinic | 1 | 2010 | 20 | 0.080 |
Why?
|
| Prognosis | 2 | 2004 | 1603 | 0.080 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2009 | 2 | 0.070 |
Why?
|
| Pharyngectomy | 1 | 2009 | 2 | 0.070 |
Why?
|
| Oropharynx | 1 | 2009 | 9 | 0.070 |
Why?
|
| Algorithms | 1 | 2012 | 560 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 589 | 0.070 |
Why?
|
| Sunlight | 2 | 2005 | 18 | 0.070 |
Why?
|
| Tretinoin | 2 | 2005 | 33 | 0.070 |
Why?
|
| Bone Diseases | 1 | 2008 | 19 | 0.070 |
Why?
|
| Mexico | 1 | 2007 | 72 | 0.070 |
Why?
|
| Microscopy | 1 | 2007 | 28 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2007 | 261 | 0.070 |
Why?
|
| Stress, Mechanical | 1 | 2007 | 102 | 0.070 |
Why?
|
| Anthralin | 1 | 2007 | 2 | 0.060 |
Why?
|
| PUVA Therapy | 1 | 2007 | 22 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 2007 | 20 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 2366 | 0.060 |
Why?
|
| Patients | 1 | 2007 | 48 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2007 | 96 | 0.060 |
Why?
|
| Women | 1 | 2006 | 13 | 0.060 |
Why?
|
| Ornithine Decarboxylase | 1 | 2005 | 1 | 0.060 |
Why?
|
| Dermabrasion | 1 | 2004 | 2 | 0.060 |
Why?
|
| Skin Aging | 1 | 2005 | 9 | 0.060 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 52 | 0.050 |
Why?
|
| Dinitrochlorobenzene | 1 | 2004 | 1 | 0.050 |
Why?
|
| Cyclobutanes | 1 | 2004 | 2 | 0.050 |
Why?
|
| Cryosurgery | 1 | 2004 | 24 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2004 | 19 | 0.050 |
Why?
|
| Folliculitis | 1 | 2004 | 1 | 0.050 |
Why?
|
| Antigens, CD1 | 1 | 2004 | 2 | 0.050 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2004 | 4 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 56 | 0.050 |
Why?
|
| Prednisone | 1 | 2004 | 70 | 0.050 |
Why?
|
| Inflammation | 2 | 2004 | 557 | 0.050 |
Why?
|
| Hirsutism | 1 | 2003 | 1 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 194 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2004 | 145 | 0.050 |
Why?
|
| Age Distribution | 1 | 2003 | 211 | 0.050 |
Why?
|
| Endpoint Determination | 2 | 2017 | 22 | 0.050 |
Why?
|
| Patient Selection | 1 | 2004 | 291 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 227 | 0.050 |
Why?
|
| Simplexvirus | 1 | 2002 | 3 | 0.050 |
Why?
|
| Acyclovir | 1 | 2002 | 14 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2002 | 22 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2002 | 54 | 0.050 |
Why?
|
| Fingers | 1 | 2002 | 78 | 0.040 |
Why?
|
| Face | 1 | 2020 | 29 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2020 | 11 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 44 | 0.040 |
Why?
|
| Medicine | 1 | 2020 | 40 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2020 | 80 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2019 | 35 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 66 | 0.040 |
Why?
|
| Pedigree | 1 | 2019 | 142 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 95 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 142 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2019 | 304 | 0.030 |
Why?
|
| Nasopharyngitis | 1 | 2018 | 2 | 0.030 |
Why?
|
| Dogs | 1 | 2018 | 130 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 46 | 0.030 |
Why?
|
| Fibrosis | 1 | 2018 | 129 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 174 | 0.030 |
Why?
|
| Injections | 1 | 2015 | 76 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2015 | 68 | 0.030 |
Why?
|
| Oceanic Ancestry Group | 1 | 2014 | 6 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 9 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 80 | 0.020 |
Why?
|
| Pain Threshold | 1 | 2012 | 105 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 2691 | 0.020 |
Why?
|
| Perception | 1 | 2012 | 107 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2012 | 385 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 4151 | 0.020 |
Why?
|
| Hyperandrogenism | 1 | 2010 | 2 | 0.020 |
Why?
|
| Fathers | 1 | 2010 | 13 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2010 | 82 | 0.020 |
Why?
|
| New York City | 1 | 2009 | 14 | 0.020 |
Why?
|
| Mothers | 1 | 2010 | 94 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2009 | 57 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 138 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 168 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 306 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2008 | 14 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 755 | 0.020 |
Why?
|
| Pamphlets | 1 | 2007 | 5 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2007 | 16 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2007 | 16 | 0.020 |
Why?
|
| Knowledge | 1 | 2007 | 15 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 397 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2007 | 61 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 8544 | 0.010 |
Why?
|
| Self Concept | 1 | 2006 | 47 | 0.010 |
Why?
|
| Chemexfoliation | 1 | 2004 | 2 | 0.010 |
Why?
|
| Lentigo | 1 | 2004 | 4 | 0.010 |
Why?
|
| Dicarboxylic Acids | 1 | 2004 | 6 | 0.010 |
Why?
|
| Nails | 1 | 2004 | 6 | 0.010 |
Why?
|
| Cryotherapy | 1 | 2004 | 13 | 0.010 |
Why?
|
| Helping Behavior | 1 | 2004 | 1 | 0.010 |
Why?
|
| Nursing Assessment | 1 | 2004 | 12 | 0.010 |
Why?
|
| Foundations | 1 | 2004 | 8 | 0.010 |
Why?
|
| Causality | 1 | 2004 | 38 | 0.010 |
Why?
|
| Health Status | 1 | 2007 | 411 | 0.010 |
Why?
|
| Information Services | 1 | 2004 | 15 | 0.010 |
Why?
|
| Self-Help Groups | 1 | 2004 | 11 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2004 | 57 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 703 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 189 | 0.010 |
Why?
|
| Hair Follicle | 1 | 2004 | 8 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 37 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 1506 | 0.010 |
Why?
|
| Self Care | 1 | 2004 | 144 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2003 | 53 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 139 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 743 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2004 | 149 | 0.010 |
Why?
|
| Social Support | 1 | 2004 | 195 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 269 | 0.010 |
Why?
|
| Registries | 1 | 2004 | 328 | 0.010 |
Why?
|
| Women's Health | 1 | 2004 | 242 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 2461 | 0.010 |
Why?
|